342 related articles for article (PubMed ID: 28742259)
1. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
2. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
Chay J; Donovan P; Cummins L; Kubler P; Pillans P
Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
[TBL] [Abstract][Full Text] [Related]
3. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases.
Vikse J; Jonsdottir K; Kvaløy JT; Wildhagen K; Omdal R
Rheumatol Int; 2019 Jun; 39(6):1083-1090. PubMed ID: 30923955
[TBL] [Abstract][Full Text] [Related]
7. Prospective data collection of off-label use of rituximab in Australian public hospitals.
O'Connor K; Liddle C
Intern Med J; 2013 Aug; 43(8):863-70. PubMed ID: 23735074
[TBL] [Abstract][Full Text] [Related]
8. Off-label use of rituximab in a tertiary Queensland hospital.
Butterly SJ; Pillans P; Horn B; Miles R; Sturtevant J
Intern Med J; 2010 Jun; 40(6):443-52. PubMed ID: 19460062
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
[TBL] [Abstract][Full Text] [Related]
10. [Review of the current use of rituximab during 4 years in a French university hospital].
Reynaud Q; Killian M; Robles A; Mounsef F; Camdessanché JP; Mariat C; Cathébras P
Rev Med Interne; 2015 Dec; 36(12):800-12. PubMed ID: 26318843
[TBL] [Abstract][Full Text] [Related]
11. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C; Pérez-Alvarez R; García-Hernández FJ; Ayala-Gutiérrez MM; Callejas JL; Martínez-Berriotxoa A; Rascón J; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Gómez-de-la-Torre R; Sáez L; Canora-Lebrato J; Camps MT; Ortego-Centeno N; Castillo-Palma MJ; Ramos-Casals M;
Arthritis Res Ther; 2011 Jul; 13(4):R112. PubMed ID: 21745378
[TBL] [Abstract][Full Text] [Related]
12. Indications for Rituximab Use in an Integrated Health Care Delivery System.
Delate T; Hansen ML; Gutierrez AC; Le KN
J Manag Care Spec Pharm; 2020 Jul; 26(7):832-838. PubMed ID: 32584674
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].
Proft F; Schulze-Koops H; Grunke M; Schrezenmeier E; Halleck F; Henes J; Unger L; Schmidt E; Fiehn C; Jacobi A; Iking-Konert C; Kneitz C; Schmidt RE; Bannert B; Voll RE; Fischer-Betz R; Kötter I; Tony HP; Holle J; Aringer M; Erler A; Behrens F; Burmester GR; Dörner T
Z Rheumatol; 2018 Feb; 77(1):28-39. PubMed ID: 28589389
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
16. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
Berntsson SG; Kristoffersson A; Boström I; Feresiadou A; Burman J; Landtblom AM
Acta Neurol Scand; 2018 Oct; 138(4):327-331. PubMed ID: 29797711
[TBL] [Abstract][Full Text] [Related]
17. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.
Shetty S; Ahmed AR
Autoimmunity; 2013 Dec; 46(8):487-96. PubMed ID: 24151854
[TBL] [Abstract][Full Text] [Related]
18. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
19. [Off-label use of biological therapies in systemic diseases].
Hachulla E
Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
[No Abstract] [Full Text] [Related]
20. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.
Mostkowska A; Rousseau G; Raynal NJ
FASEB J; 2024 Mar; 38(5):e23536. PubMed ID: 38470360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]